Cover Image
Read Now

Guanfacine hydrochloride extended-release for the treatment of attention deficit hyperactivity disorder in adults a review of clinical effectiveness, cost-effectiveness, and guidelines

The purpose of this report is to examine the clinical effectiveness, cost-effectiveness, and evidence-based guidelines regarding the use of guanfacine hydrochloride extended-release for the treatment of adults with attention deficit hyperactivity disorder (ADHD)

Bibliographic Details
Main Authors: Poitras, Veronica, McCormack, Suzanne (Author)
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa CADTH 2018, September 11, 2018
Edition:Version 1.0
Series:CADTH rapid response report: summary with critical appraisal
Subjects:
Attention Deficit Disorder With Hyperactivity / Drug Therapy
Guanfacine / Economics
Canada
Cost-benefit Analysis
Guanfacine / Standards
Treatment Outcome
Guanfacine / Therapeutic Use
Delayed-action Preparations
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The purpose of this report is to examine the clinical effectiveness, cost-effectiveness, and evidence-based guidelines regarding the use of guanfacine hydrochloride extended-release for the treatment of adults with attention deficit hyperactivity disorder (ADHD)
Physical Description:1 PDF file (19 pages) illustrations

Similar Items